We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go: Expired investment: £5,877,517
An automated platform allowing landlords to manage their properties and save time and money on fees. With brightLET's solution, there is no need for an intermediary person to be involved in the property management process. Landlords can perform administration tasks on their own tenancies, be kept up-to-date on ever-changing regulations and manage tradespeople. Specific services available to landlords include options to book viewings, upload photos, videos and floorplans, provide reports on inspections, gas safety, EPC, Right 2 Rent and PAT checks. The brightLET platform is available on almost any device, including desktops, tablets and mobile devices. brightLET has partnered with the YMCA, this has allowed the company access to a provider market and housing association worth more than £10bn. There are various user types utilising the platform, since launch 650+ landlords, 1000+ tenants and 300+ tradespeople are using brightLET to manage their properties. Their revenue model has resulted in landlords achieving savings on property fees of £450 outside London and £1,368 within London. Funds will primarily be used for growth and expansion within London, as this is where the majority of brightLET landlords are situated. The company aims to increase their brand awareness through marketing campaigns and hire talent to assist with technology developments, sales and customer support.
days to go: Expired investment: £66,932
Verto Homes have created the Zero Carbon Smart Home. These homes create and store their own clean energy from the sun, they automatically know when and where light heat and shade are needed and they manage the energy they use so efficiently that their energy bills are almost 0.
days to go: Expired investment: £1,389,280
VULSINI operates in the ‘Health & Wellness’ sector, and supplies massage related equipment to spas, hotels, colleges, massage therapists and a wide network of distributors worldwide.
days to go: Expired investment: £23,940
Their unique adiposet system dramatically improves the patient experience of breast reconstruction following breast cancer treatment, whilst improving clinical practice and reducing cost to NHS and private hospitals. Adiposet also has applications in many other therapeutic and cosmetic procedures.
days to go: Expired investment: £446,380
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
Metrion Biosciences is a pharmaceutical research organisation that provide a high quality drug discovery services for ion channel targets to clients on a fee-for-service or collaboration basis.
days to go: Expired investment: £465,150
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph